PM131

PM131 (also known as PB131) is a novel, highly selective, and brain-permeable small molecule inhibitor of histone deacetylase 6 (HDAC6). Developed by researchers at Massachusetts General Hospital, PM131 exhibits potent binding affinity with an IC50 of 1.8 nM and over 116-fold selectivity for HDAC6 over other HDAC isoforms. In preclinical models of Alzheimer's disease, PM131 has demonstrated the ability to cross the blood-brain barrier, clear amyloid-beta (Aβ) deposits by upregulating phagocytosis, preserve tubulin/microtubule network integrity by enhancing acetylated α-tubulin levels, and reduce neuroinflammation by lowering the generation of pro-inflammatory cytokines and chemokines. Additionally, PM131 has been shown to significantly reduce phosphorylated tau levels in 3D neural culture models of Alzheimer's disease. It is also being investigated for its neuroprotective and anti-inflammatory effects in other central nervous system disorders, such as ischemic stroke.

Other names

4-((3,4-Dihydro-1,8-naphthyridin-1(2H)-yl)methyl)-3-fluoro-N-hydroxybenzamideBenzamide, 4-[(3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl]-3-fluoro-N-hydroxy-